Global Cystic Fibrosis Strategic Business Report 2017 - Annual Estimates and Forecasts 2014-2022
Dublin, July 04, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Cystic Fibrosis - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Cystic Fibrosis in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2022. Market data and analytics are derived from primary and secondary research.
Key Topics Covered:
1. MARKET OVERVIEW
- Cystic Fibrosis
- A Prelude
- CF Disease Prevalence: A Brief Note
- Treatment Modalities for Cystic Fibrosis
- CFTR Modulators: Key Drug Category
- Competitive Scenario
2. RESEARCH IN CYSTIC FIBROSIS SPACE
- Areas of Research & Development
- Gene Therapy
- A Step Towards Cure
- Research Findings & Innovations
- Updated CF Diagnosis Guidelines to Aid in Diagnosis and Personalized Treatment
- Pipeline Drugs
- An Overview
- Select Pipeline Drugs for Cystic Fibrosis Treatment by Development Stage, 2016
- Description of Select Pipeline Drugs
- Ataluren
- VX-661 + Ivacaftor
- Riociguat
- QBW251
- CTP-656
- Cavosonstat (N91115)
- VX-440
- QR-010
- pGM169/GL67A
- Acebilustat
- Resunab
- Inhaled Mannitol
- VX-371
- Inhaled Levoflaxacin (Quinsair)
- AeroVanc (Vancomycin Inhalation Powder)
3. DISEASE OVERVIEW
- Cystic Fibrosis
- A Hereditary Disease
- Mutation in CFTR Gene
- A Major Cause of CF
- The Most Common Mutation that Affects CFTR Protein
- Table 3: Most Common Mutations and Worldwide Frequency (includes corresponding Graph/Chart)
- Hereditary Risk of the Disease
- Pathophysiology of the Disease
- Symptoms of Cystic Fibrosis
- Common Symptoms in Early Childhood
- Common Symptoms in Grownups or Adults:
- Complications Associated with Cystic Fibrosis
- Sinus and Lung Illness
- Pancreatic, Gastrointestinal, and Liver Disease
- Endocrine Disorders
- Infertility
- Diagnosis of Cystic Fibrosis
- Newborn Test
- Sweat Test
- The IRT Test
- Carrier Test
- Antenatal Test
- Other Common Tests
- Prenatal Diagnosis of Cystic Fibrosis
- Tests to Diagnose CF-Related Complications
- Cystic Fibrosis in Children
4. CYSTIC FIBROSIS TREATMENT: AN OVERVIEW
- Existing Treatment Options for Cystic Fibrosis
- A Quick Glance at Common Drugs for Cystic Fibrosis Management
- Analysis of Drugs Indicated for Management of Cystic Fibrosis
- Antibiotic Therapy for Lung Infections
- Select Antibiotics Approved for CF Treatment
- TOBI (Tobramycin Inhalation Solution)
- Other Common Cystic Fibrosis Infections and Recommended Antibiotics
- Cayston (Aztreonam for Inhalation Solution)
- Combination Antibiotic Therapy
- Mucolytics
- Pulmozyme
- The Effective Mucolytic Agent
- Pancreatic Enzyme Replacement Therapy (PERT) for EPI
- Leading PE Drugs Worldwide for Treating Pancreatic Insufficiency Associated with Cystic Fibrosis
- CTFR Modulators
- Bronchodilators
- Additional Treatment for Patients with CF
- Surgical and Other Techniques
- Lung Transplantation
- Recommended for Rare Cases of CF
- Feeding Tube
- For Extra Nutrition
- Bowel Surgery
- To Remove any Blockage in Bowel
5. CLINICAL STUDIES
- Vertex Pharmaceuticals Announces Positive Phase 3 Study Results of ORKAMBI
- ProQR Therapeutics Announces Positive Proof-of-Concept Study for QR-010
- Concert Pharmaceuticals Presents Positive Food Effect Results for CTP-656
- Vertex Pharmaceuticals Initiates Phase 2 Studies for VX-440 & VX-152
- Vertex Pharmaceuticals Provides Update on Phase 3 Study of VX
- 661 with ivacaftor
- Protalix BioTherapeutics Announces Start of Phase II Trial of AIR DNase (PRX-110)
- Nivalis Therapeutics Announces Completion of Enrollment for Phase 2 Study of N91115
- Alaxia SAS Announces Agreement and Grant from CFFT for ALX-009 Studies
- Polyphor Completes Successful Phase I Study of Inhaled POL6014
- AlgiPharma Receives Grant from CFFT for Phase 2 Trials of OligoG
- Health Canada Grants Clearance to ProMetic for its PBI-4050
- Cystic Fibrosis Canada Finances Laurent Pharmaceuticals' LAU- 7b Phase 2 Trial
- Galapagos NV Begins Phase 2 Study of GLPG1837
- Pharmaxis Announces Positive Phase II Trial Results of Bronchitol®
- PTC Therapeutics Completes Enrollment for second Phase 3 clinical trial of Translarna
- Anthera Pharmaceuticals Begins Phase 3 Study of Oral Liprotamase
- Parion Sciences Announces Expanded Enrollment Criteria for CLEAN-CF Trial
- Laurent Announces Positive Phase 1b Trial Results for LAU-7b
- Celtaxsys Announces Positive Phase 1 Clinical Trial Data of CTX-4430
- Corbus Pharmaceuticals Receives USFDA Clearance to Initiate Phase 2 Study of Resunab
- Savara Pharmaceuticals Unveils Positive Phase 2 Trial Results of AeroVanc
- KaloBios Reports Top-line Data from Phase 2 Study of KB001-A
- Galapagos NV Nominates GLPG2222 for Combination Therapy with GLPG1837
- Cystic Fibrosis Trust and NovaBiotics Partner for the Phase IIa Study of Lynovex
- PTC Therapeutics Initiates Phase 3 Trial of Translarna/ataluren
- Kamada to Start Clinical Study of Alpha-1 Antitrypsin (AAT) for Cystic Fibrosis
6. PRODUCT LAUNCHES/APPROVALS
- EC Grants Orphan Drug Designation to Corbus Pharmaceuticals' Resunab
- FDA Approves Vertex's ORKAMBI® for Extended Age Group
- Pharmaxis Announces Approval of Bronchitol® in Russia
- FDA Grants Orphan Drug Status to Pulmatrix's CF Drug PUR1900
- ProQR Therapeutics Announces FDA Fast Track Designation for QR-010
- Alcresta Therapeutics Launches Relizorb Cartridge
- EC Grants Orphan Medicinal Product Designation to Arch Biopartners' AB569
- TGV-Inhalonix Receives Orphan Drug Designation for its Mul-1867
- RespirTech Launches Development of Remote Monitoring System for CF
- Vertex Pharmaceuticals Receives TGA Approval of ORKAMBI®
- AlgiPharma's OligoG Receives Orphan Drug Designation by FDA
- Proteostasis Therapeutics Receives FDA Fast Track designation for PTI-428
- Proteostasis Therapeutics Expands CF Drug Pipeline
- Vertex Pharmaceuticals Receives Two EU Approvals for KALYDECO®
- USPTO Issues Patent to OrPro Therapeutics' Theradux
- FDA Approves Vertex's ORKAMBI
- Advanced Inhalation Therapies Receives Orphan Medicinal Product Designation for AIT-CF from EMA
- FDA Approves New Age Group Indication for Vertex Pharmaceuticals' KALYDECO
- Sandoz Launches Tobramycin Inhalation Solution in the US
- FDA Approves sNDA for KALYDECO
- EC Grants Orphan Designation to Macrolide CF Drug by Synovo GmbH
7. RECENT INDUSTRY ACTIVITY
- Pharmaxis Enters into Research Collaboration with Woolcock Institute
- Horizon Pharma Acquires Raptor Pharmaceutical
- AstraZeneca to Sell Drug Commercialization Rights to Pfizer
- Vertex Pharmaceuticals and Moderna Therapeutics Enter into Research Collaboration
- Editas Medicine Enters into Agreement with CFFT for CRISPR/ Cas9-based CF Drugs
- Galapagos and AbbVie Expand Agreement for CF Portfolio
- Raptor Pharmaceutical Acquires Quinsair from Tripex Pharmaceuticals
- Galapagos NV Enters into Licensing Agreement with the HUB Foundation
- Zambon SpA Acquires Nigaard Pharma
- ManRos and Cyclacel Enter into Licensing Agreement for Seliciclib
- Vertex and Parion Sciences Collaborate to Develop Investigational CF Treatment
- Ruthigen and Pulmatrix Enter into Merger Agreement
- N30 Pharmaceuticals Changes Name to Nivalis Therapeutics
- Anthera Pharmaceuticals Acquires Sollpura/liprotamase from Eli Lilly
- OPKO Health Acquires Inspiromatic dry powder inhaler from Inspiro Medical
- CURx Pharmaceuticals Enters into Global License Agreement with Gilead Sciences
8. SELECT CLINICAL-STAGE PLAYERS
- Advanced Inhalation Therapies (AIT) Ltd (Israel)
- Alaxia SAS (France)
- AlgiPharma AS (Norway)
- Anthera Pharmaceuticals, Inc. (USA)
- Arch BioPartners (Canada)
- Celtaxsys, Inc. (USA)
- Concert Pharmaceuticals, Inc. (USA)
- Corbus Pharmaceuticals Holdings, Inc.(USA)
- CURx Pharmaceuticals (USA)
- Nivalis Therapeutics, Inc. (USA)
- NovaBiotics Ltd (UK)
- Parion Sciences, Inc. (USA)
- Pharmaxis Ltd (Australia)
- PTC Therapeutics, Inc. (USA)
- Pulmatrix, Inc. (USA)
9. FOCUS ON SELECT GLOBAL PLAYERS
- AbbVie Inc. (USA)
- Galapagos NV (Belgium)
- Genentech, Inc. (USA)
- Gilead Sciences, Inc. (USA)
- Novartis AG (Switzerland)
- Vertex Pharmaceuticals (USA)
10. GLOBAL MARKET PERSPECTIVE For more information about this report visit https://www.researchandmarkets.com/research/p...c_fibrosis
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Respiratory Drugs
